GIM
IBB icon

Glenmede Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Glenmede Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.25M Sell
22,480
-500
-2% -$68.3K 0.02% 497
2025
Q2 		$2.91M Buy
+22,980
New +$2.82M 0.01% 516

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Glenmede Investment Management's IBB Position: Q3 2025 in Review

Glenmede Investment Management reduced its iShares Biotechnology ETF (IBB) stake by 2.2% in Q3 2025, selling an estimated $68.3K and leaving 22,480 shares worth $3.25M. The position accounts for 0.02% of the portfolio, ranked #497.

Glenmede Investment Management first reported a position in IBB in Q2 2025 and has held it in 2 quarters since. 803 funds tracked by Wall St. Rank hold IBB as of Q3 2025.

  • Glenmede Investment Management held 22,480 shares of iShares Biotechnology ETF worth $3.25M as of Q3 2025.
  • Glenmede Investment Management sold 500 iShares Biotechnology ETF shares in Q3 2025, an estimated $68.3K.
  • iShares Biotechnology ETF made up 0.02% of Glenmede Investment Management's portfolio in Q3 2025, its #497 holding.
  • Glenmede Investment Management first reported a position in iShares Biotechnology ETF in Q2 2025 and has held it in 2 quarters since.
  • 803 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.